Cellectis is a clinical-stage biotechnology company that specializes in the development of innovative cancer immunotherapies based on gene-edited allogeneic CAR T-cells. The company's proprietary technology platform, TALEN, enables the editing of genes with precision and specificity, which can be used to develop therapies for a wide range of diseases. Cellectis' lead product candidate, UCART22, is a gene-edited allogeneic CAR T-cell therapy currently in clinical trials for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The company is also developing a pipeline of other CAR T-cell therapies for the treatment of solid tumors and other hematologic malignancies.
Cellectis is a clinical-stage biotechnology company that specializes in the development of innovative cancer immunotherapies based on gene-edited allogeneic CAR T-cells. The company's proprietary technology platform, TALEN, enables the editing of genes with precision and specificity, which can be used to develop therapies for a wide range of diseases. Cellectis' lead product candidate, UCART22, is a gene-edited allogeneic CAR T-cell therapy currently in clinical trials for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The company is also developing a pipeline of other CAR T-cell therapies for the treatment of solid tumors and other hematologic malignancies.